Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, AbbVie, Takeda, Huadong Medicine  >>  Phase 1
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elahere (mirvetuximab soravtansine-gynx) / AbbVie
NCT03045393: Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

Withdrawn
1
0
US
Mirvetuximab Soravtansine (IMGN853)
Duke University, National Comprehensive Cancer Network
Breast Cancer Triple Negative
02/18
02/18
IMGN-0401, NCT01609556: First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Checkmark Pooled analysis data from trials for ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Pooled analysis data from trials for ovarian cancer at ESMO 2022
Checkmark Safety and activity in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
Dec 2016 - Dec 2016: Safety and activity in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
Checkmark ASCO 2016
More
Completed
1
206
Canada, US
Mirvetuximab soravtansine, IMGN853
ImmunoGen, Inc.
Tumors
03/18
03/18
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Completed
1
25
US
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
06/22
12/22
NCI-2016-01913, NCT02996825: Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Completed
1
44
US
Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacological Study
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
02/24
02/24
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Completed
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
02/25
02/25

Download Options